Extent of Drug Patents With Terminal Disclaimers and Obviousness-Type Double Patenting Rejections.
作者信息
Tu S Sean, Kesselheim Aaron S, Chao Bernard
机构信息
West Virginia University College of Law, Morgantown.
Division of Pharmacoepidemiology and Pharmacoeconomics, Brigham and Women's Hospital, Boston, Massachusetts.
出版信息
JAMA. 2024 Sep 10;332(10):837-838. doi: 10.1001/jama.2024.14350.
Abstract
摘要
相似文献
1
Extent of Drug Patents With Terminal Disclaimers and Obviousness-Type Double Patenting Rejections.带有权利要求书放弃声明的药品专利范围以及显而易见型重复专利驳回情况。
JAMA. 2024 Sep 10;332(10):837-838. doi: 10.1001/jama.2024.14350.
2
A "Method of Use" to Prevent Generic and Biosimilar Market Entry.一种防止仿制药和生物类似药进入市场的“使用方法”。
N Engl J Med. 2023 Feb 9;388(6):483-485. doi: 10.1056/NEJMp2216020. Epub 2023 Jan 25.
3
Possible anticompetitive agreements between brand, generic companies to be studied.品牌公司与仿制药公司之间可能存在的反竞争协议有待研究。
Am J Health Syst Pharm. 2000 Dec 1;57(23):2140, 2142. doi: 10.1093/ajhp/57.23.2140.
4
The Eleventh Circuit holds that agreements in which pharmaceutical companies pay generic companies not to compete may be valid.美国第十一巡回上诉法院认为，制药公司向仿制药公司支付费用以避免竞争的协议可能是有效的。
J Law Med Ethics. 2004 Spring;32(1):181-4.
5
The "reverse payment paradox": an overview of the legality of reverse exclusionary payments in the pharmaceutical industry.“反向支付悖论”：制药行业反向排他性支付的合法性概述
Health Care Law Mon. 2010 Mar;2010(3):2-10.
6
Targeting Unconscionable Prescription-Drug Prices - Maryland's Anti-Price-Gouging Law.针对不合理的处方药价格——马里兰州的反价格欺诈法。
N Engl J Med. 2017 Jul 13;377(2):101-103. doi: 10.1056/NEJMp1704907. Epub 2017 Jun 7.
7
Supreme Court to decide whether payments by patent holders to delay production of generics are anticompetitive.美国最高法院将裁决专利持有人为延迟仿制药生产而支付款项是否具有反竞争性。
BMJ. 2012 Dec 12;345:e8464. doi: 10.1136/bmj.e8464.
8
A generic problem.一个一般性问题。
Nat Clin Pract Gastroenterol Hepatol. 2006 Dec;3(12):649. doi: 10.1038/ncpgasthep0659.
9
Patent Portfolios Protecting 10 Top-Selling Prescription Drugs.专利组合保护十大畅销处方药。
JAMA Intern Med. 2024 Jul 1;184(7):810-817. doi: 10.1001/jamainternmed.2024.0836.
10
A shift on "pay for delay"--reopening doors for pharmaceutical competition?“支付延迟”的转变——为药品竞争重新打开大门？
N Engl J Med. 2012 Nov 1;367(18):1681-3. doi: 10.1056/NEJMp1209693.
引用本文的文献
1
Why N,N-dimethyltryptamine matters: unique features and therapeutic potential beyond classical psychedelics.为什么N，N-二甲基色胺很重要：超越传统迷幻剂的独特特征和治疗潜力。
Front Psychiatry. 2024 Nov 6;15:1485337. doi: 10.3389/fpsyt.2024.1485337. eCollection 2024.
Zotero 插件